.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,871,759

« Back to Dashboard

Claims for Patent: 8,871,759

Title:Inhibitors of hepatitis C virus replication
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. ##STR00001##
Inventor(s): Coburn; Craig A. (Royersford, PA), Ludmerer; Steven W. (North Wales, PA), Liu; Kun (Edison, NJ), Wu; Hao (Shanghai, CN), Soll; Richard (San Diego, CA), Zhong; Bin (Shanghai, CN), Zhu; Jian (Shanghai, CN)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/260,684
Patent Claims: 1. A compound having the structure: ##STR00531##

2. A compound having the structure: ##STR00532##

3. A pharmaceutical composition comprising (i) an amount of the compound of claim 1 effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3, further comprising one or more additional therapeutic agents selected from the group consisting of HCV antiviral agents, immunomodulators and anti-infective agents.

5. The pharmaceutical composition of claim 4, wherein said one or more additional therapeutic agents is selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.

6. A method of treating a patient infected with HCV comprising the step of administering the compound of claim 1, in an amount effective to treat infection by HCV in said patient.

7. A pharmaceutical composition comprising (i) an amount of the compound of claim 2 effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

8. The pharmaceutical composition of claim 7, further comprising one or more additional therapeutic agents selected from the group consisting of HCV antiviral agents, immunomodulators and anti-infective agents.

9. The pharmaceutical composition of claim 8, wherein said one or more additional therapeutic agents is selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.

10. A method of treating a patient infected with HCV comprising the step of administering the compound of claim 2, in an amount effective to treat infection by HCV in said patient.

11. A pharmaceutically acceptable salt of a compound having the structure: ##STR00533##

12. A pharmaceutical composition comprising (i) an amount of the pharmaceutically acceptable salt of the compound of claim 11 effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 12, further comprising one or more additional therapeutic agents selected from the group consisting of HCV antiviral agents, immunomodulators and anti-infective agents.

14. The pharmaceutical composition of claim 13, wherein said one or more additional therapeutic agents is selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.

15. A method of treating a patient infected with HCV comprising the step of administering the compound of claim 11, in an amount effective to treat infection by HCV in said patient.

16. A pharmaceutically acceptable salt of a compound having the structure: ##STR00534##

17. A pharmaceutical composition comprising (i) an amount of the pharmaceutically acceptable salt of the compound of claim 16 effective for inhibition of HCV viral replication, and (ii) a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17, further comprising one or more additional therapeutic agents selected from the group consisting of HCV antiviral agents, immunomodulators and anti-infective agents.

19. The pharmaceutical composition of claim 18, wherein said one or more additional therapeutic agents is selected from the group consisting of HCV protease inhibitors and HCV NS5B polymerase inhibitors.

20. A method of treating a patient infected with HCV comprising the step of administering the compound of claim 16, in an amount effective to treat infection by HCV in said patient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc